Adline Chem Lab

Adline Chem Lab Liabilities

Delisted·Sep 16, 2026

The The Liabilities of Adline Chem Lab (524604.BO) as of Nov 5, 2026 is 16.29 M INR. In the previous year, The Liabilities was 22.26 M INR — a change of -26.82% (lower).

Liabilities

16.29 MINR

YoY

-26.82%

Last updated:

In 2023, Adline Chem Lab's total liabilities amounted to 16.29 M INR, a -26.82% difference from the 22.26 M INR total liabilities in the previous year.

The Adline Chem Lab Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2021
37.03 M INR
Jan 1, 2022
22.26 M INR
Jan 1, 2023
16.29 M INR
The Adline Chem Lab Liabilities history
YEARLiabilitiesYoY
16.29 MINR-26.82%
22.26 MINR-39.88%
37.03 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Adline Chem Lab Stock analysis

What does Adline Chem Lab do? Adline Chem Lab Ltd. manufactures pharmaceutical products for domestic and international markets. The company's domestic product lines include anti-infectives, bone health, gastroenterology care, hemostatic, multi-vitamins, pediatric care, pain and inflammation, pregnancy and reproductive care, respiratory care, and hepatocare. For international markets, the firm offers tablets, capsules, and injections. Veterinary products such as B Complex Liver Extract With Vitamin B12 Inection, Chlorpheniramine Injection IP, Triflupromazine Hydrochloride Injection IP, Triamcinolone Acctonide Injection IP, Triamcinolone Acetonide IP, and Tetracyclin-bolus Tablets are sold to veterinary clients. Educational supplements like Demo-Dose Dyaz, Demo-dose colac, Demo-Dose Dilat, and Demo-Eose eryth target healthcare professionals for product demonstration purposes. The domestic market segments purchase pharmaceuticals for human health needs, while international buyers acquire tablets, capsules, and injections for global distribution. Veterinary clients specifically buy the listed veterinary products for animal health applications. Educational supplements are purchased by healthcare professionals to demonstrate product efficacy during training sessions. Adline Chem Lab Ltd. generates revenue through the sale of pharmaceutical products to domestic consumers, international distributors, veterinary practices, and healthcare professionals. The company's domestic market focuses on human health solutions, while international sales emphasize standardized dosage forms. Veterinary product sales cater to animal health sectors, and educational supplements support product education within the medical community. Adline Chem Lab is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Adline Chem Lab's Liabilities

Adline Chem Lab's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Adline Chem Lab's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Adline Chem Lab's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Adline Chem Lab's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Adline Chem Lab’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Adline Chem Lab stock

The Liabilities of Adline Chem Lab is 16.29 M INR in 2023.

The Liabilities of Adline Chem Lab changed from 22.26 M INR to 16.29 M INR, representing a -26.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Adline Chem Lab since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Adline Chem Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Adline Chem Lab

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Adline Chem Lab